IMAX 'Odyssey Effect' Fuels Bullish Article, But Valuation and Backlog Risks Keep DeepValue at Wait

What happened

A Seeking Alpha article dated October 6, 2026 reiterates a Buy rating, citing The Odyssey launch and FY2026 guidance for 52% worldwide box office growth and 5.6 percentage points EBITDA margin expansion, driving an expected EPS CAGR acceleration to 19.5% for FY25-29. However, the DeepValue master report maintains a WAIT rating at $43.40, arguing the current price already reflects a strong second-half 2026 slate and premium-format share, with limited upside until trailing global share reclaims 3.8% and backlog stabilizes after falling to 421 systems from 501. The article's projections exceed even the bull case implied value of $51, which requires global share above 3.9% and backlog growth above 435, conditions not yet evident. Key risks from recent filings include 17 Greater China cancellations, a sharp drop in IMAX China earnings, and $110.5 million cash trapped in the PRC, which could offset ex-China strength. While The Odyssey may have performed well, the article's forecasts rely on sustained box office momentum and margin expansion that are unconfirmed, and the stock's 57.8x P/E and 18.8x EV/EBITDA leave little margin of safety.

Implication

The Seeking Alpha article's bullish scenario is plausible but not yet supported by hard data, and the DeepValue WAIT rating remains appropriate given the stock's full valuation. Upside to $51 requires durable global share above 3.9% and a reversal in backlog declines, which have not been demonstrated; recent filings show backlog fell to 421 and IMAX China earnings dropped sharply. Downside to $35 is possible if China contract attrition continues and ex-China growth fails to offset, as seen in the 1H 2026 IMAX China net income decline from $23.7M to $8.1M. The balance sheet is solid with $551M total liquidity, but that does not justify paying 57.8x earnings for a cyclical, content-dependent business. Monitor the next 10-Q for backlog at or above 421, trailing global share near 3.8%, and stabilization in China; until then, a pullback toward $37 offers a more favorable risk-reward.

Thesis delta

No shift in base thesis: WAIT. The new article reinforces the bull case's tailwinds from strong content, but it does not resolve the bear concerns around backlog contraction and China weakness. If The Odyssey's global box office proves durable and upcoming filings show share above 3.8% and backlog growth, an upgrade to Accumulate would be warranted; otherwise, current valuation already prices in optimistic assumptions.